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Non-enzymatic modifications of proteins have been implicated in the pathogenesis of diabetes, atherosclerosis, and neurodegenerative diseases as well as in normal aging (1– 4). These
modifications can arise from direct exposure to reactive oxygen,
chlorine, or nitrogen species or from reaction with low molecular weight reactive carbonyl compounds derived from carbohydrates, lipids, or amino acids (5–7). These carbonyl compounds react primarily with lysine and arginine residues,
forming both adducts and cross-links in protein. Examples
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include the formation of N⑀-(carboxymethyl)lysine (CML)1 by
reaction of GO or GLA with lysine, the formation of carboxyethyllysine by the reaction of MGO with lysine, the formation
of argpyrimidine in the reaction between MGO and arginine,
and lysine-lysine cross-links derived from the reactions of this
amino acid with GO or MGO (8 –11). Less reactive carbonyl
compounds, such as glucose and other reducing sugars, can
also react with proteins by forming intermediate Amadori adducts that may undergo further rearrangement, dehydration,
and oxidation reactions to form stable AGEs, such as pentosidine and CML (12, 13). Carbonyl products of lipid peroxidation,
malondialdehyde and hydroxynonenal, have been shown to
react with protein lysine residues forming advanced lipoxidation end products (14). In vivo, the relative significance of
different pathways of protein modification by carbonyl compounds would depend on the specific conditions, such as the
level of oxidative stress and the status of carbonyl scavenging
mechanisms.
Reactive carbonyl species are formed in a variety of metabolic reactions. Some are generated by non-oxidative pathways
such as the formation of MGO by the spontaneous decomposition of triose phosphates or during anaerobic metabolism of
acetone and amino acids (15). Other carbonyl species derive
from oxidative reactions. For example, GO, MGO, and GLA are
formed during the autoxidation of carbohydrates (8, 9, 16).
Lipid peroxidation reactions can also produce GO and MGO (6,
17). Carbonyl compounds dehydroascorbate, acrolein, and
MGO are also produced during the oxidation of ascorbate,
hydroxyamino acids, and polyunsaturated fatty acids, respectively (5, 7, 18).
Because carbonyl modification reactions can alter protein
structure and function and cause the formation of high molecular weight protein aggregates, they have been implicated in
the development of a number of pathologies via a condition
known as “carbonyl stress” (4, 19, 20). Therefore, inhibition of
synthesis and/or trapping of free and protein-bound carbonyls
presents an important avenue for drug development. Therapeutic agents such as aminoguanidine, L-arginine, OPB-9195,
tenilsetam, and metformin have been proposed to trap reactive
carbonyl compounds (21–25).
We have recently demonstrated that pyridoxamine, a natu-

1
The abbreviations used are: CML, N⑀-(carboxymethyl)lysine; AGE,
advanced glycation end product; BSA, bovine serum albumin; DNPH,
2,4-dinitrophenylhydrazine; GO, glyoxal; GOPM, GO-pyridoxamine adduct; GLA, glycolaldehyde; GLAPM, GLA-pyridoxamine adduct; MGO,
methylglyoxal; PM, pyridoxamine; RNase, bovine pancreatic ribonuclease A; ELISA, enzyme-linked immunosorbent assay; ESI-LC/MS, electrospray ionization-liquid chromatography/mass spectrometry; HPLC,
high pressure liquid chromatography.
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Reactive carbonyl compounds are formed during autoxidation of carbohydrates and peroxidation of lipids.
These compounds are intermediates in the formation of
advanced glycation end products (AGE) and advanced
lipoxidation end products (ALE) in tissue proteins
during aging and in chronic disease. We studied the reaction of carbonyl compounds glyoxal (GO) and glycolaldehyde (GLA) with pyridoxamine (PM), a potent postAmadori inhibitor of AGE formation in vitro and of
development of renal and retinal pathology in diabetic
animals. PM reacted rapidly with GO and GLA in neutral, aqueous buffer, forming a Schiff base intermediate
that cyclized to a hemiaminal adduct by intramolecular
reaction with the phenolic hydroxyl group of PM. This
bicyclic intermediate dimerized to form a five-ring
compound with a central piperazine ring, which was
characterized by electrospray ionization-liquid chromatography/mass spectrometry, NMR, and x-ray crystallography. PM also inhibited the modification of lysine
residues and loss of enzymatic activity of RNase in the
presence of GO and GLA and inhibited formation of the
AGE/ALE N⑀-(carboxymethyl)lysine during reaction of
GO and GLA with bovine serum albumin. Our data suggest that the AGE/ALE inhibitory activity and the therapeutic effects of PM observed in diabetic animal models
depend, at least in part, on its ability to trap reactive
carbonyl intermediates in AGE/ALE formation, thereby
inhibiting the chemical modification of tissue proteins.
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EXPERIMENTAL PROCEDURES

Materials—D-Ribose, GLA, PM(HCl)2, DNPH, lanthanum nitrate
hexahydrate, yeast RNA, and BSA were purchased from Sigma. GO and
Girard’s reagent T were from Aldrich; RNase A was from Worthington
Biochemical.
Incubation Conditions—All reactions were performed at 37 °C in 200
mM sodium phosphate buffer, pH 7.5. Sodium azide (0.02%) was added
to prevent bacterial growth.
ELISA Detection of CML-BSA—The formation of CML in reactions
between BSA and carbonyl compounds was measured by ELISA. The
ELISA measurements used polyclonal anti-AGE antibody R618 (1:350)
and were performed as described previously (29, 30, 32). CML has been
identified as a dominant antigen for polyclonal antibodies against glycated proteins (33, 34). To determine the epitope specificity of our
polyclonal antibody R618, we purified the antibody by affinity chromatography on CML-BSA-coupled Pierce AminoLink Plus column. The
reactivity of purified antibody toward several AGE-modified proteins
was identical to that of unpurified antibody,2 indicating that CML was
the primary epitope recognized by R618 polyclonal antibody.
Measurements of RNase Activity—RNase activity was determined by
measuring the formation of acid-soluble oligonucleotide as described by
Kalnitsky et al. (35), with some modifications. For the assay, 100 l of
3 g/ml RNase in 100 mM sodium acetate, pH 5.0, was mixed with 100
l of 1% yeast RNA in the same buffer. After the incubation at 37 °C for
5 min, the reaction was stopped by the addition of 100 l of an ice-cold
solution of 0.8% lanthanum nitrate in 18% perchloric acid. Incubation
tubes were kept on ice for 5 min to ensure complete precipitation of
undigested RNA and then centrifuged at 12,000 ⫻ g for 10 min. An
aliquot of the supernatant (20 l) was diluted to 1 ml with distilled
water, and the amount of digested (solubilized) RNA was determined by
measuring absorbance at 260 nm. The activity of RNase incubated
either alone or with PM at 37 °C was monitored separately and used as
the reference for each incubation time. This reference activity did not
change significantly over the course of incubation.
Determination of Reactive Dicarbonyl and Carbonyl Groups—The
concentration of GO was determined using Girard’s reagent T (36).
Briefly, an aliquot (5 l of 10 mM solution of GO) was mixed with 995 l
of 120 mM sodium borate, pH 9.3. An aliquot of this mixture (200 l) was
then added to 800 l of 100 mM Girard’s reagent T in the same sodium
borate buffer. After the reaction had reached equilibrium (10 min at
room temperature), the amount of reacted dicarbonyl groups was determined by measuring absorbance at 326 nm (36).
The concentration of GLA was determined by the DNPH assay (37).
Aliquots (20 l) of the samples containing 10 mM glycolaldehyde were
mixed with 1 ml of 200 M DNPH in 1 M HCl. After 20 min at room
temperature, the amount of reacted carbonyls was determined by meas-

2
B. Cussimanio, R. G. Khalifah, and B. G. Hudson, unpublished
data.

uring absorbance at 380 nm (37).
Mass Spectrometry—ESI-LC-MS/MS was carried out in a positive ion
mode on a Micromass Quattro LC mass spectrometer (Micromass, Beverly, MA) equipped with a Hewlett-Packard (Palo Alto, CA) series 1100
HPLC system and a Keystone (Bellefonte, PA) Aquasil C-18 microbore
column. The solvent system consisted of 0.1% trifluoroacetic acid (solvent A) and methanol (solvent B), flow rate at 0.8 ml/min. The gradient
was as follows: 0 –2 min, 15% B; 2– 40 min, 15–75% B, hold 5 min; 45–55
min, 75–15% B, hold 20 min. In some experiments, samples were
analyzed by direct injection ESI-mass spectrometry. In this case, the
carrier buffer consisted of 80% acetic acid and 20% methanol, flow rate
at 0.03 ml/min.
X-ray Crystallography—Colorless crystals of GOPM (0.28 ⫻ 0.20 ⫻
0.16 mm) or GLAPM (0.24 ⫻ 0.20 ⫻ 0.08 mm) were coated in inert oil,
mounted on the end of a thin glass fiber, and transferred to the cold
stream of a Bruker SMART APEX charged coupled device-based diffractometer system (molybdenum K␣ radiation, l ⫽ 0.71073 Å). The
x-ray intensity data were measured at 190°K. Crystal quality and
initial unit cell parameters were determined based on reflections taken
from a set of three scans measured in orthogonal regions of reciprocal
space. Subsequently a hemisphere of frame data was collected with a
scan width of 0.3° and an exposure time of 20 s per frame. The first 50
frames were recollected at the end of the data set to monitor crystal
decay. The raw data frames were integrated into reflection intensity
files using the software SAINT⫹ (38), which also applied corrections for
Lorentz and polarization effects.
The unit cell parameters were as follows: for GOPM, a ⫽ 18.3459 Å,
b ⫽ 14.8104 Å, c ⫽ 12.8368 Å, ␣ ⫽ 90°, ␤ ⫽ 119.123°, ␥⫽90°; for
GLAPM, a ⫽ 17.5912 Å, b ⫽ 8.7332 Å, c ⫽ 18.6798 Å, ␣ ⫽ 90°, ␤ ⫽
93.8200°, ␥ ⫽ 90°. The final unit cell parameters are based on the least
squares refinement of 3867 and 5943 reflections (for GOPM and
GLAPM, respectively) with I ⬎ 5(s)I. Analysis of the data showed
negligible crystal decay during data collection. No correction for absorption was applied. GOPM and GLAPM crystallized in the space group
C2/c as determined by the systematic absences in the intensity data.
The structure was solved by a combination of direct methods and
difference Fourier syntheses and refined by full matrix least squares
against F2 using the SHELXTL software (39). The protonated GOPM
species is situated about a crystallographic inversion center. The asymmetric unit therefore contains half of the GOPM cation and one trichloroacetate anion. For the diprotonated GLAPM cation, the asymmetric
unit also contains one-half of the cation and one trichloroacetate anion.
All non-hydrogen atoms were refined with anisotropic displacement
parameters. Hydrogen atoms were placed in idealized positions and
refined using a riding model except for H1n bound to N1, which was
located and refined with an isotropic displacement parameter.
Solution NMR—NMR data were collected on a Varian Inova 500
MHz instrument using deuterated dimethyl sulfoxide as solvent. Structural characterization of GOPM was provided by gradient-enhanced
heteronuclear multiple quantum coherence, gradient-enhanced heteronuclear multiple quantum-multiple bond coherence, distortionless enhancement by polarization transfer, 1H, and 13C NMR.
Absorbance Measurements—Absorbance and absorbance spectra
were measured using a Hewlett-Packard 8452A diode array spectrophotometer equipped with a Peltier temperature control unit. The concentration of modified proteins was determined using second derivative
analysis of absorbance spectra to exclude a contribution from carbonyl
modification-related spectral components (40).
RESULTS

Reaction of PM with GO and GLA—Because PM possesses a
nucleophilic amino group (see Fig. 6), it has the potential to
react with carbonyl compounds. We therefore measured the
loss of reactive carbonyl and dicarbonyl groups in solutions of
10 mM GO or 10 mM GLA during the course of incubation with
15 mM PM. In our earlier studies, this concentration of PM was
effective at inhibiting the formation of CML from the proteinAmadori intermediate in vitro (28 –30).
PM reacted with both GO and GLA and trapped these carbonyl compounds (Fig. 1). The reaction of PM with GO was
notably faster than with GLA (t1⁄2 ⫽ 0.94 and 5.0 h, respectively). Because GLA can be oxidized to GO (9), it was important to
establish whether oxidation was necessary for the reaction of
PM with GLA. The rate of GLA oxidation was relatively slow
under our experimental conditions. After 72 h of incubation,
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ral intermediate of vitamin B6 metabolism, prevented the development of nephropathy in the rat model of diabetes (Baynes
and co-authors, Refs. 26 and 27). Our earlier studies of the
mechanism of action of PM suggest that it acts by inhibiting
the conversion of intermediates in protein glycation reactions
(Amadori compounds) to advanced glycation end products, such
as CML (Hudson and co-authors, Refs. 28 –30), and by trapping
reactive intermediates formed during lipid peroxidation (31).
In the present report, we extend our studies into the mechanism of action of PM by showing that it also inhibits protein
modifications by GO and GLA, major products of sugar and
lipid degradation. Pyridoxamine exerts this protective effect by
competing with protein lysine residues for dicarbonyl and ␣-hydroxycarbonyl moieties of GO and GLA, respectively, to form
relatively stable cyclic aminal derivatives, GOPM and GLAPM.
Based on this work, we propose that the therapeutic effects of
pyridoxamine observed in diabetic animal models (26, 27) are,
in part, the result of its action in trapping a wide range of
carbonyl intermediates in the pathway of protein modification
by sugars and lipids. We suggest that pyridoxamine acts
through this mechanism in addition to its inhibition of postAmadori protein modifications established in our earlier studies (28 –30).

Mechanism of AGE Inhibition by Pyridoxamine
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FIG. 2. Effect of GO on the absorbance spectrum of PM in
solution. PM (15 mM) was incubated with GO (10 mM) in 200 mM
sodium phosphate buffer, pH 7.5, at 37 °C (A). Insoluble complex was
removed at various times by brief centrifugation, and the absorbance
spectrum of the supernatant was recorded following 200-fold dilution
into phosphate buffer. Thin lines represent the absorbance spectrum of
the supernatant solution after 0.5, 2, and 4 h of incubation of PM with
GO. After 16 h of incubation, no further spectral change was observed.
Complex collected by centrifugation was washed with water, vacuumdried, and dissolved in 0.5% trichloroacetic acid (B). Solution pH was
adjusted to pH 7.5 by 200-fold dilution into 200 mM sodium phosphate
buffer, and the absorbance spectrum was recorded. The presence of
traces of trichloroacetic acid did not affect the absorbance spectrum of
pyridoxamine in phosphate buffer.

when ⬃90% of GLA had reacted with PM (Fig. 1B), only 21% of
GLA had been converted to GO, as determined in separate
incubations using the Girard’s T assay (data not shown). Thus,
PM appeared to react directly with both GLA and GO, as was
also confirmed below by structural analysis of reaction products. Importantly, the reactivity of PM with GO was significantly greater than that of free amino acid lysine even though
the lysine amino groups were at 2-fold excess over the amino
groups of PM (Fig. 1A). In a slower reaction with GLA, PM still
trapped this carbonyl compound more rapidly than did lysine
(Fig. 1B).
To purify the GOPM adduct, we took advantage of its low
solubility. Under the conditions of our experiments (10 mM GO
and 15 mM PM), a visible precipitate formed during the course
of reaction and was isolated by centrifugation at different incubation times. Although the absorbance of the solution gradually decreased, it still exhibited absorbance maxima characteristic of PM at neutral pH (256 and 324 nm) as shown in Fig.
2A. The GOPM precipitate (2 mg) was dissolved in 3 ml of 0.5%
trichloroacetic acid, and an aliquot of this solution was then
diluted 200-fold into sodium phosphate buffer, pH 7.5. The
spectrum of GOPM complex was significantly different from
that of PM itself: the short wavelength maximum shifted to 282
nm and its relative intensity was increased (Fig. 2B). Reactions
of PM and GLA proceeded more slowly but also yielded a
precipitate. Similar changes in absorbance spectra were also

observed, suggesting the formation of similar products from
GO and GLA (data not shown).
Structures of GOPM and GLAPM Adducts—A direct injection electrospray ionization mass spectrometry analysis of
GOPM and GLAPM produced protonated molecular ions
[M⫹H]⫹ with m/z ⫽ 417 and 385, respectively (Fig. 3, A and B).
The other prominent ions present in the spectra of GOPM and
GLAPM (m/z ⫽ 209 and 193, respectively) were doubly charged
molecular ions [M⫹2H]2⫹ based on the spacing of 13C isotope
satellites of these ions at 0.5 atomic mass units and by their
identical HPLC elution time with [M⫹H]⫹ ions. Fragmentation
mass spectra (MS/MS) of all ions yielded peaks at m/z ⫽ 169
and 152, characteristic of the molecular ion and deamination
product of PM, respectively (data not shown). To unequivocally
establish novel structures of GOPM and GLAPM, we have
performed solution 1H and 13C NMR and x-ray crystallography
experiments. The results (Table I and Fig. 3, A and B, insets)
were consisted with the structures shown in Fig. 3C.
PM Inhibition of Chemical Modification of Proteins by GO
and GLA—To investigate the efficiency of protection of protein
from carbonyl stress, we evaluated the effect of PM on the
chemical modification of RNase A and BSA by GO and GLA in
vitro. BSA contains 58 lysines per molecule, and its chemical
modification can be followed by ELISA measurement of CML.
RNase, on the other hand, has two active site lysines, Lys-7 and
Lys-41 (41); therefore, the enzyme loses activity on reaction
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FIG. 1. PM forms adducts with GO and GLA. Samples of 10 mM
glyoxal (A) or 10 mM glycolaldehyde (B) were incubated with 15 mM
pyridoxamine (triangles) or 15 mM lysine (30 mM amino group)
(squares). The incubations were carried out at 37 °C in 200 mM sodium
phosphate buffer, pH 7.5, containing 0.02% sodium azide. The loss of
carbonyl moieties in the course of the reaction was measured spectrophotometrically using either Girard’s reagent T or DNPH as described
under “Experimental Procedures.” Parallel experiments with carbonyl
compounds incubated under the same conditions but without PM or
lysine were used as references for calculating the relative amount
of reactive carbonyl groups. Note the different time scales in panels A
and B.
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1

H and

Carbon atoma

13

TABLE I
C NMR chemical shifts of GOPM
1

H NMR
ppm

C-2
C-3
C-4
C-5
C-6
C-7
C-9
C-11
C-11 (-OH)
C-12
C-13
C-13 (-OH)
a

7.89 (1H,s)
4.60 (1H,d), 4.18 (1H,d)
4.70 (1H,d)
4.59 (1H,d), 4.9 (1H,d)
5.54 (1H,d)
2.67 (3H,s)
4.45 (2H,d)
5.12 (1H,t)

13

C NMR
ppm

144.2
148.4
127.6
130.8
138.1
45.12
86.1
80.46, 87.63
18.26
58.18

For carbon atom numbering, see Fig. 3C.

with carbonyl compounds. The incubations were carried out at
equimolar concentrations of GO or GLA, PM, and protein lysines (6.7 mM) to compare the reactivity of PM and protein
amino groups with carbonyl compounds.
Although the inhibition of RNase activity by GO and GLA
occurred with different kinetics, only about 20% of enzyme
activity was detected after 288 h of incubation with either
carbonyl compound (Fig. 4, A and B). When RNase was incubated with these carbonyl compounds, but in the presence of
PM, a protection of enzyme activity was observed. The protection was more prominent in the case of GO as compared with

GLA (Fig. 4, A and B), which is consistent with the lower
reactivity of PM toward GLA (Fig. 1).
Because PM reacted more rapidly with GO or GLA as compared with lysine (Fig. 1), we predicted that PM would also
inhibit the modification of protein lysine residues by reactive
carbonyl compounds, specifically the formation of CML, a common product of the reaction of proteins with GO and GLA (9).
As shown in Fig. 5, PM inhibited the GO- and GLA-induced
formation of CML-BSA. In contrast to the results of experiments with RNase, PM was more effective in inhibiting the
formation of CML from GLA as compared with GO. This was
also evident at lower molar ratios of PM to carbonyl compounds
(Fig. 5, A and B, insets). Because the reaction between PM and
GLA is slower when compared with the reaction between PM
and GO (Fig. 1), these results imply the participation of an
additional inhibitory mechanism that is different from carbonyl scavenging. Interestingly, Glomb and Monnier (9) have
found that the conversion of GO to CML does not include a
metal-catalyzed oxidative step, whereas the GLA-induced
CML-BSA synthetic pathway has an alternative metal-catalyzed oxidative step and thus depends, in part, on the presence
of transition metal ions. Transition metal ions, such as Cu2⫹,
occur naturally in the sodium phosphate buffer that was used
in our experiments (42). These ions were catalytically active
under our experimental conditions because chelation with diethylenetriaminepentaacetic acid partially inhibited GLA-induced but not GO-induced CML formation (data not shown),
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FIG. 3. ESI-mass spectra and structures of GOPM (A) and
GLAPM (B) adducts. Purified adducts were dissolved in 0.5% acetic
acid and analyzed by the direct injection ESI-mass spectrometry. Structures of GOPM and GLAPM adducts were analyzed by x-ray crystallography as described under “Experimental Procedures” (A and B, insets). C, chemical structures of GOPM and GLAPM consistent with the
data of mass spectrometry, x-ray crystallography, and solution NMR.
For 1H and 13C NMR chemical shifts of GOPM, see Table I.

FIG. 4. PM inhibits inactivation of RNase by GO (A) and GLA
(B). RNase (8.3 mg/ml, 6.7 mM amino groups) and corresponding reactive carbonyl compound (6.7 mM) were incubated either in the absence
(circles) or presence (triangles) of 6.7 mM pyridoxamine. For the controls, RNase was incubated alone without any additives (squares). The
incubations were carried out at 37 °C in 200 mM sodium phosphate
buffer, pH 7.5, containing 0.02% sodium azide. At the indicated times,
aliquots were withdrawn, and RNase activity was determined as described under “Experimental Procedures.” Each point represents an
average of duplicate measurements.

Mechanism of AGE Inhibition by Pyridoxamine

which is consistent with the mechanism proposed by Glomb
and Monnier (9). Because PM itself can chelate divalent metal
ions (43, 44), this property may contribute to more efficient
inhibition of GLA-induced CML formation by PM.
DISCUSSION

Advanced protein glycation reactions, originally studied because of their role in the “browning” of food products, are now
considered to be one of the major sources of protein modifications in chronic diseases and during normal aging (1–3). Although new AGEs are being discovered continuously, the general outline of the chemistry of AGE synthesis is relatively well
understood. In the Maillard reaction, sugars and proteins interact directly. The Schiff base product of this reaction rearranges to an Amadori intermediate that, in turn, is converted
to AGEs (see Fig. 7, step 1), most prominently to CML (13),
which is detected at an increased concentration in animal and
human tissues in diabetes, neurodegenerative diseases, and
aging (45– 48). AGE modifications have been implicated as a
source of structural and functional damage of proteins in diseases such as diabetes (49 –51). Sugar or protein-sugar intermediates can also degrade, largely through sugar autoxidation
(Wolff pathway, Ref. 52) or through the degradation of the
Schiff base intermediate (Namiki pathway, Ref. 53), to produce
low molecular weight carbonyl compounds. Reactive carbonyls
are also produced during lipid peroxidation reactions (see Fig.

7). These electrophilic compounds can react directly with proteins to form adducts with lysine or arginine side chains (9, 54),
as schematically shown in Fig. 7, steps 2 and 3. Steady-state
levels of reactive carbonyls such as GO and MGO are increased
in the plasma of diabetic animals and in patients with diabetes
and uremia (55–58).
The carbonyl stress hypothesis emphasizes the role of carbonyl compounds, derived from different sources, in the induction of pathogenic protein modifications (4, 19, 20). In this
study, we have demonstrated that PM can protect model proteins from carbonyl stress by chemically trapping low molecular weight carbonyl compounds. A proposed mechanism of formation of GOPM and GLAPM is shown in Fig. 6. Reaction
between PM and GO begins with nucleophilic attack of the
primary amine of PM on a carbonyl group of GO (Fig. 6A, step
1). The tetrahedral carbinolamine eliminates water to yield an
imine (Schiff base), which undergoes nucleophilic attack by the
phenolate anion aromatic hydroxyl to form a six-membered
hemiaminal ring (Fig. 6A, steps 2– 4). This monomeric intermediate then condenses with a second molecule of the intermediate to form the final product, GOPM (Fig. 6A, steps 5 and 6).
GLA and PM react along a similar pathway to form a similar
product (Fig. 6B). However, after the formation of the sixmembered ring, this reaction is more likely to proceed via an
aziridine intermediate at neutral pH. An aziridine is formed
between the secondary amine of PM and the methylene carbon
of GLA, resulting in a partial positive charge on the methylene
carbon (Fig. 6B, step 5). The electrophilic nature of the methylene carbon makes it a candidate for nucleophilic attack by
another molecule of the intermediate (Fig. 6B, step 6). As in the
formation of GOPM, two molecules of the intermediate condense to form the final product, GLAPM (Fig. 6B, step 7).
It is important to note that the inhibitory effects of PM are
not limited to scavenging of low molecular weight carbonyl
products of glycation reactions. As demonstrated in our earlier
works (28 –30), PM strongly inhibits the conversion of postAmadori intermediate to CML. In more recent work, Onorato et
al. (31) showed that PM inhibits advanced lipoxidation reactions by trapping lipid-derived intermediates. Thus, under in
vitro conditions, PM appears to inhibit the principal steps that
lead to chemical modification of proteins by low molecular
weight carbonyl compounds derived from either sugars or lipids, in addition to its inhibition of the formation of AGEs
derived from Amadori adducts (Fig. 7).
Clearly, the efficacy of PM in vivo will be influenced by
factors such as the nature of carbonyl species and local tissue
concentrations of reactive carbonyls and PM, as well as the
concentrations of endogenous carbonyl scavengers. However,
even very small amounts of reactive carbonyls that exceed the
capacity of endogenous carbonyl scavenger systems (e.g. glyoxalase pathway) may lead, over a long time, to high levels of
protein modifications. By trapping the excess of reactive carbonyls, PM may provide a significant protective effect. It is
important to note that the steady-state concentration of PM
reaches ⬃100 M in the plasma of PM-treated animals (26, 27),
whereas the concentrations of GO, MGO, malondialdehyde,
and hydroxynonenal are in the nanomolar to low micromolar
range (58, 59). Thus, the plasma concentration of PM is sufficient to scavenge the ambient concentration of major reactive
carbonyl intermediates. Because the metastable adducts
formed between PM and GO or GLA are small when compared
with proteins, they would be rapidly eliminated from the body
in urine. Therefore, the dynamic equilibrium between GO/GLA
adducts to PM and to protein amino groups would lead to the
gradual depletion of these reactive carbonyl compounds from
plasma. The trapping reaction by PM would also be favored by
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FIG. 5. PM inhibits formation of CML during exposure of BSA
to GO and GLA. Carbonyl compounds (6.7 mM) and BSA (7.5 mg/ml,
6.7 mM amino groups) were incubated alone (circles) or with 6.7 mM
pyridoxamine (triangles) for the indicated times. The incubations were
carried out at 37 °C in 200 mM sodium phosphate buffer, pH 7.5,
containing 0.02% sodium azide. CML-modified BSA was measured by
ELISA as described under “Experimental Procedures.” Each point represents an average of duplicate measurements. Inset, inhibition of formation of CML-BSA by different concentrations of PM, measured after
288 h of incubation.
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PM can alleviate nephropathy and other diabetes-related complications in streptozotocin-diabetic rats. In agreement with
our proposed mechanism of action (Fig. 7), PM treatment has
resulted in lower levels of CML in the skin collagen of diabetic
rats (26, 27). Moreover, the hexanoic acid amide derivative of
PM was quantified by mass spectrometry in urine from PMtreated rats, indicating that pyridoxamine traps reactive intermediates of lipid peroxidation in vivo (27).

FIG. 7. A model of carbonyl stress-induced protein modifications and mechanism of PM inhibition. The numbers represent the
sites of inhibition by PM. In previous work (28 –30), we have shown that
(step 1) PM is a potent inhibitor of the formation of AGE-modified
proteins from protein-Amadori precursors. In the present work, we
show that PM also traps reactive low molecular weight carbonyl compounds derived from either (step 2) sugars or (step 3) lipids, inhibiting
the AGE and advanced lipoxidation end product modifications of proteins. HNE, hydroxynonenal; MDA, malondialdehyde.

the stabilization of GOPM and GLAPM in the hemiaminal
form. Interestingly, when PM and GO were incubated at concentrations of 100 M, the reaction product consistent with
Schiff base or cyclic hemiaminal was detected by ESI-LC-MS,3
as predicted by the reaction mechanism proposed in Fig. 6.
Recently, Baynes and co-authors (26, 27) have reported that
3
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